CAR-engineered immune cells reportedly slowed blood cancers and solid tumors in mice

A post describes researchers expanding granulocyte-monocyte progenitors, immature cells that can develop into other immune cells, and engineering them with chimeric antigen receptors (CARs) to recognize targets on cancer cells. It says the cells established themselves in mouse bone marrow, generated more immune cells and slowed blood cancers and solid tumors. An immune-activating signal further strengthened the antitumor response. The findings are preclinical.